VBI Vaccines (NASDAQ:VBIV) Upgraded to “Hold” by ValuEngine

VBI Vaccines (NASDAQ:VBIV) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, May 2nd.

Several other equities research analysts also recently weighed in on VBIV. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Noble Financial restated a “buy” rating on shares of VBI Vaccines in a research note on Friday, March 23rd. Finally, BidaskClub cut shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $9.42.

VBI Vaccines opened at $3.53 on Wednesday, Marketbeat Ratings reports. The company has a quick ratio of 3.72, a current ratio of 3.77 and a debt-to-equity ratio of 0.11. VBI Vaccines has a 1-year low of $3.20 and a 1-year high of $3.33.

VBI Vaccines (NASDAQ:VBIV) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.03). VBI Vaccines had a negative return on equity of 47.54% and a negative net margin of 4,607.13%. The company had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.21 million. equities research analysts anticipate that VBI Vaccines will post -0.7 earnings per share for the current fiscal year.

In other news, insider Francisco Diaz-Mitoma acquired 10,000 shares of the business’s stock in a transaction on Friday, May 11th. The stock was bought at an average price of $3.05 per share, with a total value of $30,500.00. Following the completion of the acquisition, the insider now owns 268,839 shares of the company’s stock, valued at $819,958.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 54.50% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its position in VBI Vaccines by 36.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 58,200 shares of the biopharmaceutical company’s stock worth $249,000 after acquiring an additional 15,400 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in VBI Vaccines by 24.8% during the fourth quarter. TIAA CREF Investment Management LLC now owns 78,369 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 15,557 shares during the last quarter. California State Teachers Retirement System boosted its position in VBI Vaccines by 52.5% during the fourth quarter. California State Teachers Retirement System now owns 54,460 shares of the biopharmaceutical company’s stock worth $233,000 after acquiring an additional 18,760 shares during the last quarter. Kamunting Street Capital Management L.P. boosted its position in VBI Vaccines by 64.4% during the fourth quarter. Kamunting Street Capital Management L.P. now owns 49,308 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 19,308 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in VBI Vaccines by 54.2% in the 4th quarter. Bank of New York Mellon Corp now owns 68,478 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 24,072 shares during the last quarter. Institutional investors and hedge funds own 48.51% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply